Literature DB >> 3587912

Proliferative vitreoretinopathy. The mechanism of development of vitreoretinal traction.

B M Glaser, A Cardin, B Biscoe.   

Abstract

Proliferative vitreoretinopathy (PVR) is the leading cause of failure of retinal detachment surgery. In this disorder, contractile cellular membranes form within the vitreous cavity. Retinal pigment epithelial (RPE) cells are an early and important component of these membranes. Contraction is mediated by cellular events and this contraction results in the formation of traction retinal detachments. Using the techniques of time-lapse cinemicrography, the authors studied the interaction of single RPE cells with individual strands of collagen. RPE cells pull the collagen fibers toward them using alternating extension and retraction of their lamellipodia. (The mechanism can be likened to sailors pulling in sheets of a sal in a hand-over-hand manner.) The collagen is not engulfed by the cell, but instead is piled up in a small bundle adjacent to the cell. Using this mechanism, each cell can reel in several times its length of collagen in 1 hour. In this manner, a small number of RPE cells may be able to collapse the vitreous gel and exert tractional forces.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 3587912     DOI: 10.1016/s0161-6420(87)33443-8

Source DB:  PubMed          Journal:  Ophthalmology        ISSN: 0161-6420            Impact factor:   12.079


  40 in total

1.  Intravitreal invading cells contribute to vitreal cytokine milieu in proliferative vitreoretinopathy.

Authors:  I A El-Ghrably; H S Dua; G M Orr; D Fischer; P J Tighe
Journal:  Br J Ophthalmol       Date:  2001-04       Impact factor: 4.638

2.  Proliferative retinal diseases: myofibroblasts cause chronic vitreoretinal traction.

Authors:  R Walshe; P Esser; P Wiedemann; K Heimann
Journal:  Br J Ophthalmol       Date:  1992-09       Impact factor: 4.638

Review 3.  Extracellular matrix contraction by fibroblasts: peptide promoters and second messengers.

Authors:  C Guidry
Journal:  Cancer Metastasis Rev       Date:  1992-03       Impact factor: 9.264

4.  The effect of X-ray irradiation on human retinal pigment epithelial cell proliferation.

Authors:  T Ohuchi; S Kuriyama; N Yoshimura; Y Honda; M Hiraoka; M Abe
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1991       Impact factor: 3.117

5.  Anti-EMP2 diabody blocks epithelial membrane protein 2 (EMP2) and FAK mediated collagen gel contraction in ARPE-19 cells.

Authors:  Shawn A Morales; David G Telander; Sergey Mareninov; Agnes Nagy; Madhuri Wadehra; Jonathan Braun; Lynn K Gordon
Journal:  Exp Eye Res       Date:  2012-06-19       Impact factor: 3.467

Review 6.  The pars plana incision: experimental studies, pathologic observations, and clinical experience.

Authors:  A E Krieger
Journal:  Trans Am Ophthalmol Soc       Date:  1991

7.  Growth factors outside the PDGF family drive experimental PVR.

Authors:  Hetian Lei; Gisela Velez; Peter Hovland; Tatsuo Hirose; Debra Gilbertson; Andrius Kazlauskas
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-03-25       Impact factor: 4.799

8.  [Vitreal-induced RPE cell traction. Investigation of pathological vitreous samples in an in vitro contraction model].

Authors:  J Beutel; M Lüke; K-U Bartz-Schmidt; S Grisanti
Journal:  Ophthalmologe       Date:  2009-10       Impact factor: 1.059

9.  Ranibizumab is a potential prophylaxis for proliferative vitreoretinopathy, a nonangiogenic blinding disease.

Authors:  Steven Pennock; David Kim; Shizuo Mukai; Matthew Kuhnle; Dal W Chun; Joanne Matsubara; Jing Cui; Patrick Ma; David Maberley; Arif Samad; Robert J Van Geest; Sarit L Oberstein; Reinier O Schlingemann; Andrius Kazlauskas
Journal:  Am J Pathol       Date:  2013-04-09       Impact factor: 4.307

10.  Measurement of cellular proliferation within the vitreous during experimental proliferative vitreoretinopathy.

Authors:  C M Yang; K R Olsen; E Hernandez; S W Cousins
Journal:  Graefes Arch Clin Exp Ophthalmol       Date:  1992       Impact factor: 3.117

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.